CA2320843A1 - Procedes mettant en application pla2 en tant que marqueur de metastases et afin de diagnostiquer des cancers selectionnes - Google Patents

Procedes mettant en application pla2 en tant que marqueur de metastases et afin de diagnostiquer des cancers selectionnes Download PDF

Info

Publication number
CA2320843A1
CA2320843A1 CA002320843A CA2320843A CA2320843A1 CA 2320843 A1 CA2320843 A1 CA 2320843A1 CA 002320843 A CA002320843 A CA 002320843A CA 2320843 A CA2320843 A CA 2320843A CA 2320843 A1 CA2320843 A1 CA 2320843A1
Authority
CA
Canada
Prior art keywords
cancer
pla2
patient
levels
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002320843A
Other languages
English (en)
Inventor
Francis E. Wilkinson
John Burczak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diadexus Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2320843A1 publication Critical patent/CA2320843A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des procédés servant à contrôler chez un patient un cancer n'ayant pas formé de métastases, afin de rechercher l'apparition de métastases, ce qui consiste à mesurer les niveaux de PLA¿2? chez ce patient. Elle concerne également des procédés servant à diagnostiquer un cancer et à en contrôler la progression, la rémission, la réponse à la thérapie et la stabilisation en fonction des niveaux de PLA¿2?.
CA002320843A 1998-02-23 1999-02-12 Procedes mettant en application pla2 en tant que marqueur de metastases et afin de diagnostiquer des cancers selectionnes Abandoned CA2320843A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US7550498P 1998-02-23 1998-02-23
US60/075,504 1998-02-23
US11193898A 1998-07-08 1998-07-08
US09/111,938 1998-07-08
US17550498A 1998-10-20 1998-10-20
US09/175,504 1998-10-20
PCT/US1999/003170 WO1999042830A1 (fr) 1998-02-23 1999-02-12 Procedes mettant en application pla2 en tant que marqueur de metastases et afin de diagnostiquer des cancers selectionnes

Publications (1)

Publication Number Publication Date
CA2320843A1 true CA2320843A1 (fr) 1999-08-26

Family

ID=27372697

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002320843A Abandoned CA2320843A1 (fr) 1998-02-23 1999-02-12 Procedes mettant en application pla2 en tant que marqueur de metastases et afin de diagnostiquer des cancers selectionnes

Country Status (4)

Country Link
EP (1) EP1057024A4 (fr)
JP (1) JP3524876B2 (fr)
CA (1) CA2320843A1 (fr)
WO (1) WO1999042830A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL131887A0 (en) * 1999-09-14 2001-03-19 Dpharm Ltd Phospholipid prodrugs of anti-proliferative drugs
ES2416344T3 (es) * 2004-02-03 2013-07-31 Diadexus, Inc. Métodos para determinar la actividad de Lp-PLA2.
US8080384B2 (en) 2006-04-05 2011-12-20 Yokohama City University Method for determination of prognosis of prostate cancer, and diagnostic agent for use in the method
CN101460090B (zh) * 2006-06-05 2013-11-20 福思光子学有限公司 表征组织的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747264A (en) * 1996-08-02 1998-05-05 Smithkline Beechum Corporation Method of diagnosing and monitoring prostate cancer
AU3743997A (en) * 1996-08-02 1998-02-25 Smithkline Beecham Corporation A novel method of detecting and treating cancer

Also Published As

Publication number Publication date
WO1999042830A1 (fr) 1999-08-26
JP2002511564A (ja) 2002-04-16
EP1057024A4 (fr) 2002-10-30
EP1057024A1 (fr) 2000-12-06
JP3524876B2 (ja) 2004-05-10

Similar Documents

Publication Publication Date Title
US20180238896A1 (en) Free ngal as a biomarker for cancer
US20100209944A1 (en) Adamts-7 as a biomarker for cancers of epithelial origin
US20070218512A1 (en) Methods related to mmp26 status as a diagnostic and prognostic tool in cancer management
WO2008039774A1 (fr) Marqueurs associés à une membrane et marqueurs extracellulaires du cancer de la prostate
JP2010513901A (ja) 癌バイオマーカー
US20180238890A1 (en) Methods and materials for detection, diagnosis and management of ovarian cancer
KR102246699B1 (ko) 암 검출을 위한 뉴클레오솜-전사 인자 복합체의 용도
JP2008502891A (ja) 乳癌のマーカーとしてのタンパク質ｐｄｘ１の使用
WO2016195051A1 (fr) Panel de biomarqueurs de plasma permettant le diagnostic du cancer du pancréas
JP3677210B2 (ja) 前立腺がんを診断し、モニターし、そして病期決定する新規な方法
CA2320843A1 (fr) Procedes mettant en application pla2 en tant que marqueur de metastases et afin de diagnostiquer des cancers selectionnes
US7288383B2 (en) Eosinophil-derived neurotoxin as a marker for ovarian cancer
KR102280360B1 (ko) 암의 진단용 조성물
KR102325742B1 (ko) 암의 진단용 조성물
KR102325731B1 (ko) 암의 진단용 조성물
KR102280672B1 (ko) 암의 진단용 조성물
KR102316892B1 (ko) 암의 진단용 조성물
US20230074311A1 (en) Composition for cancer diagnosis
KR102433983B1 (ko) 암의 진단용 조성물
KR102433986B1 (ko) 암의 진단용 조성물
KR20210109726A (ko) 암의 진단용 조성물
KR20210109725A (ko) 암의 진단용 조성물
KR100931997B1 (ko) 간세포암 종양 마커로서의 ｋｌｋ-5 유전자 및 이를 이용한간세포암 진단 방법
AU2012326434A1 (en) Predictive biomarkers for breast cancer
TW201839395A (zh) 癌症偵測方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued